Aethlon Medical Return on Equity (ROE) Growth & History (AEMD)
Aethlon Medical's return on equity was −142.89% for fiscal 2026.
View full Aethlon Medical company overviewAethlon Medical annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2026 | 2026-03-31 | −142.89% | +102.99 pp |
| 2025 | 2025-03-31 | −245.88% | −128.67 pp |
| 2024 | 2024-03-31 | −117.21% | −42.16 pp |
| 2023 | 2023-03-31 | −75.06% | +3.79 pp |
| 2022 | 2022-03-31 | −78.84% | +4.88 pp |
| 2021 | 2021-03-31 | −83.72% | +23.99 pp |
| 2020 | 2020-03-31 | −107.72% | +37.03 pp |
| 2019 | 2019-03-31 | −144.75% | +22.04 pp |
| 2018 | 2018-03-31 | −166.79% | +486.04 pp |
| 2017 | 2017-03-31 | −652.83% | −203.39 pp |
| 2016 | 2016-03-31 | −449.44% | — |
Aethlon Medical quarterly return on equity
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q1 2027 | 2026-06-30 | −30.70% | +10.53 pp |
| Q4 2026 | 2026-03-31 | −32.49% | +99.78 pp |
| Q3 2026 | 2025-12-31 | −32.40% | +1.50 pp |
| Q2 2026 | 2025-09-30 | −32.44% | +5.67 pp |
| Q1 2026 | 2025-06-30 | −41.23% | −5.71 pp |
| Q4 2025 | 2025-03-31 | −132.27% | −96.01 pp |
| Q3 2025 | 2024-12-31 | −33.90% | +4.76 pp |
| Q2 2025 | 2024-09-30 | −38.11% | −12.20 pp |
| Q1 2025 | 2024-06-30 | −35.52% | −12.22 pp |
| Q4 2024 | 2024-03-31 | −36.26% | −21.01 pp |
| Q3 2024 | 2023-12-31 | −38.66% | −23.32 pp |
| Q2 2024 | 2023-09-30 | −25.90% | −4.02 pp |
| Q1 2024 | 2023-06-30 | −23.30% | −5.09 pp |
| Q4 2023 | 2023-03-31 | −15.25% | +4.83 pp |
| Q3 2023 | 2022-12-31 | −15.34% | −3.79 pp |
| Q2 2023 | 2022-09-30 | −21.89% | −13.51 pp |
| Q1 2023 | 2022-06-30 | −18.21% | −5.98 pp |
| Q4 2022 | 2022-03-31 | −20.08% | +1.47 pp |
| Q3 2022 | 2021-12-31 | −11.55% | +7.79 pp |
| Q2 2022 | 2021-09-30 | −8.38% | +3.82 pp |
| Q1 2022 | 2021-06-30 | −12.23% | −0.82 pp |
| Q4 2021 | 2021-03-31 | −21.55% | +5.17 pp |
| Q3 2021 | 2020-12-31 | −19.33% | +20.81 pp |
| Q2 2021 | 2020-09-30 | −12.20% | +251.28 pp |
| Q1 2021 | 2020-06-30 | −11.41% | +104.35 pp |
| Q4 2020 | 2020-03-31 | −26.72% | +30.72 pp |
| Q3 2020 | 2019-12-31 | −40.14% | +14.12 pp |
| Q2 2020 | 2019-09-30 | −263.48% | −233.66 pp |
| Q1 2020 | 2019-06-30 | −115.76% | −95.57 pp |
| Q4 2019 | 2019-03-31 | −57.44% | −33.09 pp |
| Q3 2019 | 2018-12-31 | −54.26% | −3.70 pp |
| Q2 2019 | 2018-09-30 | −29.82% | — |
| Q1 2019 | 2018-06-30 | −20.19% | — |
| Q4 2018 | 2018-03-31 | −24.35% | +424.70 pp |
| Q3 2018 | 2017-12-31 | −50.56% | +34933.66 pp |
| Q4 2017 | 2017-03-31 | −449.05% | −391.06 pp |
| Q3 2017 | 2016-12-31 | −34,984.22% | −34947.61 pp |
| Q2 2017 | 2016-09-30 | −1,233.55% | −1206.27 pp |
| Q1 2017 | 2016-06-30 | −214.38% | −172.80 pp |
| Q4 2016 | 2016-03-31 | −57.99% | +23.14 pp |
| Q3 2016 | 2015-12-31 | −36.60% | — |
| Q2 2016 | 2015-09-30 | −27.29% | — |
| Q1 2016 | 2015-06-30 | −41.58% | — |
| Q4 2015 | 2015-03-31 | −81.13% | — |
Aethlon Medical return on equity trends
Over the last five fiscal years, Aethlon Medical's return on equity decreased from −83.72% to −142.89%, a change of −59.17 percentage points. The latest reported quarter, Q1 2027, shows −30.70%.
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Aethlon Medical source filings ↗